YERVOY (ipilimumab)
ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB · METASTATIC MALIGNANT MELANOMA ·+8
BMS PRIMARYCARE
Drug class
Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib
The classification string "Antineoplastic-Cytotoxic T-Lymp. Read more about Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib
2 drugs in this class 2 manufacturers
Drugs in Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib
IMJUDO (tremelimumab-actl)
ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB · LIVER CELL CARCINOMA ·+1
AstraZeneca Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib preselected. Add indication or manufacturer filters there.
The classification string "Antineoplastic-Cytotoxic T-Lymp.
antigen (CTLA-4),R-MC Antib" represents an administrative formulary heading denoting antineoplastic recombinant monoclonal antibodies targeting cytotoxic T-lymphocyte–associated antigen 4.
Biologically categorized as immune checkpoint inhibitors, these therapeutic antibodies—such as ipilimumab and tremelimumab—bind to CTLA-4 receptors on T cells to block inhibitory signals from CD80 and CD86 ligands, thereby disinhibiting and augmenting antitumor T-cell immune responses.
They are principally indicated for the treatment of advanced solid malignancies, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, malignant pleural mesothelioma, and hepatocellular carcinoma, often administered either as monotherapy or in combination with other immunotherapeutic regimens.
-
nih.gov
The classification string "Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib" represents an administrative formulary heading denoting antineoplastic recombinant monoclonal antibodies targeting cytotoxic T-lymphocyte–associated antigen 4 They are principally indicated for the treatment of advanced solid malignancies, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, malignant pleural mesothelioma, and hepatocellular carcinoma, often administered either as...
-
la.gov
The classification string "Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib" represents an administrative formulary heading denoting antineoplastic recombinant monoclonal antibodies targeting cytotoxic T-lymphocyte–associated antigen 4
-
sfhp.org
The classification string "Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib" represents an administrative formulary heading denoting antineoplastic recombinant monoclonal antibodies targeting cytotoxic T-lymphocyte–associated antigen 4
-
cancercenter.com
Biologically categorized as immune checkpoint inhibitors, these therapeutic antibodies—such as ipilimumab and tremelimumab—bind to CTLA-4 receptors on T cells to block inhibitory signals from CD80 and CD86 ligands, thereby disinhibiting and augmenting antitumor T-cell immune responses They are principally indicated for the treatment of advanced solid malignancies, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, malignant pleural mesothelioma, and hepatocellular c...
-
patsnap.com
Biologically categorized as immune checkpoint inhibitors, these therapeutic antibodies—such as ipilimumab and tremelimumab—bind to CTLA-4 receptors on T cells to block inhibitory signals from CD80 and CD86 ligands, thereby disinhibiting and augmenting antitumor T-cell immune responses
-
aacrjournals.org
Biologically categorized as immune checkpoint inhibitors, these therapeutic antibodies—such as ipilimumab and tremelimumab—bind to CTLA-4 receptors on T cells to block inhibitory signals from CD80 and CD86 ligands, thereby disinhibiting and augmenting antitumor T-cell immune responses They are principally indicated for the treatment of advanced solid malignancies, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, malignant pleural mesothelioma, and hepatocellular c...
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.